Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04416984
Title Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA-2) (ALPHA-2)
Acronym ALPHA2
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Allogene Therapeutics
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | ESP | CAN | AUS


No variant requirements are available.